Jul 06, 2013, 02.50 PM | Source: CNBC-TV18
Gautam Sinha Roy of Motilal Oswal Securities expects 7-8 percent upside in Lupin in near term.
Gautam Sinha Roy (more)
VP-Equity Strategy & Product, Motilal Oswal | Capital Expertise: Equity - Fundamental
"So, lot of positive tailwinds are there for Lupin. That is the main reason why we continue to like this stock at this point of time," he added.
The company's US-based subsidiary Gavis Pharmaceut
Lupin's US subsidiary, Gavis Pharmaceuticals LLC.,
Avinash Gorakshakar, Market Expert is of the view
Prakash Gaba of prakashgaba.com is of the view tha
"Acotiamide is a first-in-class novel drug to be i